BioSpace News Archive

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that Stephen Yoder, president and chief executive officer of Pieris, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York City.

Navidea Biopharmaceuticals, Inc. announced that it received a Notice on June 1, 2023 from the NYSE American LLC stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide.

Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for olverembatinib for the treatment of patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had received first-line treatment.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee.

ORIC Pharmaceuticals, Inc. announced that on June 1, 2023, ORIC granted a total of 3,380 non-qualified stock options and 560 restricted stock units to one new non-executive employee who began their employment with ORIC in May 2023.

EpicentRx, Inc. (“EpicentRx”) today presented clinical progress updates for two lead oncology treatment candidates, RRx-001 and AdAPT-001, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL and virtually.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.

MEDSIR announced the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer.